Combining S63845 with docetaxel in two TNBC PDX mouse models, or trastuzumab in a HER2-amplified PDX mouse model, has been shown to significantly impair tumor growth and prolong survival, although monotherapy with the MCL-1 inhibitor failed to markedly prevent tumor growth [117]. Here, ERBB2 is linked to neoplasm.